Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Capital Expenditures (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Capital Expenditures for 12 consecutive years, with $17000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 183.33% to $17000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $103000.0, a 78.13% decrease, with the full-year FY2025 number at $228000.0, down 30.7% from a year prior.
  • Capital Expenditures was $17000.0 for Q4 2025 at Aytu Biopharma, roughly flat from $17000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $329000.0 in Q2 2024 to a low of -$13.1 million in Q2 2021.
  • A 3-year average of -$1.8 million and a median of $17000.0 in 2025 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: plummeted 123.21% in 2021, then soared 183.33% in 2025.
  • Aytu Biopharma's Capital Expenditures stood at -$13.1 million in 2021, then soared by 100.05% to $6000.0 in 2024, then skyrocketed by 183.33% to $17000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Capital Expenditures are $17000.0 (Q4 2025), $17000.0 (Q2 2025), and $69000.0 (Q1 2025).